Literature DB >> 9377818

Chronic infection in the etiology of atherosclerosis--the case for Chlamydia pneumoniae.

S Gupta1, A J Camm.   

Abstract

Established cardiovascular risk factors do not fully explain the variations in the prevalence and severity of coronary heart disease. Recent evidence suggests that common chronic infections may contribute, either by direct or indirect mechanisms, to the etiology and/or progression of coronary atherosclerosis. Of the candidate infectious agents implicated, Chlamydia pneumoniae has emerged as the most likely pathogen to have a causal role. Evidence for this is based on seroepidemiologic, pathologic, and laboratory-based evidence, in addition to recent small-scale antibiotic intervention studies. Concerted efforts are now focused on the design of large prospective trials with antibiotics active against C. pneumoniae in the secondary prevention of coronary heart disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9377818      PMCID: PMC6655955          DOI: 10.1002/clc.4960201008

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  4 in total

1.  Inhibition of Chlamydia pneumoniae replication in human aortic smooth muscle cells by gamma interferon-induced indoleamine 2, 3-dioxygenase activity.

Authors:  L G Pantoja; R D Miller; J A Ramirez; R E Molestina; J T Summersgill
Journal:  Infect Immun       Date:  2000-11       Impact factor: 3.441

2.  Chronic Chlamydia pneumoniae infection may promote coronary artery disease in humans through enhancing secretion of interleukin-4.

Authors:  R Clancy; Z Ren; G Pang; P Fletcher; C D'Este
Journal:  Clin Exp Immunol       Date:  2006-11       Impact factor: 4.330

Review 3.  Antibiotic trials for coronary heart disease.

Authors:  Jeffrey L Anderson; Joseph B Muhlestein
Journal:  Tex Heart Inst J       Date:  2004

4.  Chlamydophila pneumoniae infection and cardiovascular disease.

Authors:  Rajnish Joshi; Bidita Khandelwal; Deepti Joshi; Om Prakash Gupta
Journal:  N Am J Med Sci       Date:  2013-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.